Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.2.443

MMP2 Gene-735 C/T and MMP9 gene -1562 C/T Polymorphisms in JAK2V617F Positive Myeloproliferative Disorders  

Sag, Sebnem Ozemri (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Gorukmez, Ozlem (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Ture, Mehmet (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Gorukmez, Orhan (Department of Medical Genetics, Sevket Yilmaz Education and Research Hospital)
Topak, Ali (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Sahinturk, Serdar (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Ocakoglu, Gokhan (Department of Biostatistics, Division of Hematology, Faculty of Medicine, Uludag University)
Gulten, Tuna (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Ali, Ridvan (Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Uludag University)
Yakut, Tahsin (Department of Medical Genetics, Division of Hematology, Faculty of Medicine, Uludag University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.2, 2015 , pp. 443-449 More about this Journal
Abstract
Background: Myeloproliferative disorders (MPDs) are clonal hematologic malignancies originating at the level of the pluripotent hematopoietic stem cell. Matrix metalloproteases (MMPs) are proteolytic enzymes that contribute to all stages of malignancy progression. Genetic variants in the MMP genes may influence the biological function of these enzymes and change their role in carcinogenesis and progression. To our knowledge, this is the first investigation of associations between the -735 C/T and -1562 C/T polymorphisms in the MMP2 and MMP9 genes, respectively, and the risk of essential thrombocytosis (ET), and polycythemia vera (PV). Materials and Methods: The case-control study included JAK2V617F mutation positive 102 ET and PV patients and 111 controls. Polymorphisms were determined by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and electrophoresis. Results: No statistically significant differences were detected between patient (ET+PV) and control groups regarding genotype distribution for MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms and C/T allele frequency (p>0.050). Statistically borderline significance was observed between PV and control groups regarding genotype distribution for the MMP9 gene -1562 C/T polymorphism (p=0.050, OR=2.26, 95%Cl=0.99-5.16). Conclusions: Consequently this study supported that CC genotype of MMP9 gene -1562 C/T polymorphism may be related with PV even if with borderline significance.
Keywords
Matrix metalloproteases; polymorphism; myeloproliferative disorders;
Citations & Related Records
Times Cited By KSCI : 6  (Citation Analysis)
연도 인용수 순위
1 Zhou Y, Yu C, Miao X, et al (2005). Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis, 26, 1117-21.   DOI
2 Awakura Y, Ito N, Nakamura E, et al (2006). Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett, 241, 59-63.   DOI
3 Barbui T, Barosi G, Birgegard G, et al (2011). Philadelphianegative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol, 29, 761-70.   DOI
4 Bayramoglu A, Urhan Kucuk M, Guler HI, et al (2013). Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension? Cytotechnology, Nov 21. [Epub ahead of print]
5 Besses C, Cervantes F, Pereira A, et al (1999). Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia, 13, 150-4.   DOI
6 Buggins AG, Levi A, Gohil S, et al (2011). Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol, 154, 216-22.   DOI
7 Dameshek W (1951). Some speculations on the myeloproliferative syndromes. Blood, 6, 372-5.
8 Decock J, Paridaens R, Ye S (2008). Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet, 73, 197-211.
9 Egeblad M, Werb Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-74.   DOI
10 Ennis BW, Matrisian LM (1994). Matrix degrading metalloproteinases. J Neuro Oncol, 18, 105-9.   DOI
11 Gentner B, Wein A, Croner RS, et al (2009). Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res, 29, 67-74.
12 Gruppo Italiano Studio Policitemia (1995). Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med, 123, 656-64.   DOI
13 Guo XT, Wang JF, Zhang LY, Xu GQ (2012). Quantitative assessment of the effects of MMP-2 polymorphisms on lung carcinoma risk. Asian Pac J Cancer Prev, 13, 2853-6.   DOI
14 Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C (2008). The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol, 87, 1-10.
15 Harendza S, Lovett DH, Panzer U, et al (2003). Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem, 278, 20490-9.   DOI
16 Hewitt R, Dan K (1996). Stromal cell expression of components of matrixdegrading protease systems in human cancer. Enzyme Protein, 49, 163-73.
17 Hu C, Wang J, Xu Y, et al (2013). Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene, 517, 65-71.   DOI   ScienceOn
18 Kaushansky K (2006). Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders. Cytokine Growth Factor Rev, 17, 423-30.   DOI
19 Kuittinen O, Savolainen ER, Koistinen P, Mottonen M, Turpeenniemi-Hujanen T (2001). MMP-2 and MMP-9 expression in adult and childhood acute lymphatic leukemia (ALL). Leuk Res, 25, 125-31.   DOI
20 Lacchini R, Jacob-Ferreira AL, Luizon MR, et al (2012). Common matrix metalloproteinase 2 gene haplotypes may modulate left ventricular remodelling in hypertensive patients. J Hum Hypertens, 26, 171-7.   DOI
21 Lane WJ, Dias S, Hattori K, et al (2000). Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood, 96, 4152-9.
22 Langers AM, Sier CF, Hawinkels LJ, et al (2008). MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. Br J Cancer, 98, 820-3.
23 Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13.   DOI   ScienceOn
24 Li Y, Jin X, Kang S, et al (2006). Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol, 101, 92-6.   DOI
25 Majka M, Janowska-Wieczorek A, Ratajczak J, et al (2000). Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood, 96, 4142-51.
26 Malaponte G, Polesel J, Candido S, et al (2013). IL-6-174 G > C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine, 62, 64-9.   DOI
27 Marchioli R, Finazzi G, Landolfi R, et al (2005). Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol, 23, 2224-32.   DOI
28 Marquez-Curtis LA, Dobrowsky A, Montano J, et al (2001). Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures. Br J Haematol, 115, 595-604.   DOI
29 Mehtap O, Atesoglu EB, Tarkun P, et al (2012). The association between gene polymorphisms and leukocytosis with thrombotic complications in patients with essential thrombocythemia and polycythemia vera. Turk J Haematol, 29, 162-9.   DOI
30 Matrisian LM (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet, 6, 121-5.   DOI
31 Ogawa M, Kawamoto M, Yamanaka N (2000). Matrix metalloproteinase and tissue inhibitor of metalloproteinase in human bone marrow tissues-an immunohistochemical study. J Nippon Med Sch, 67, 235-41.   DOI
32 Palei AC, Sandrim VC, Amaral LM, et al (2012). Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy. Pharmacogenomics J, 12, 489-98.   DOI
33 Park KS, Kim SJ, Kim KH, Kim JC (2011). Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol, 26, 391-7.   DOI
34 Payandeh M, Zadeh FS, Zare ME, et al (2011). Evalution of common genetic disorders in myeloproliferative neoplasms. IJHOSCR, 5, 16-20.
35 Pereza N, Ostojic S, Volk M, Kapovic M, Peterlin B (2012). Matrix metalloproteinases 1, 2, 3 and 9 functional single-nucleotide polymorphisms in idiopathic recurrent spontaneous abortion. Reprod Biomed Online, 24, 567-75.   DOI
36 Price SJ, Greaves DR, Watkins H (2000). Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific transcriptional regulation. J Biol Chem, 276, 7549-58.
37 Rollin J, Regina S, Vourc'h P, et al (2007). Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer, 56, 273-80.   DOI
38 Scott LM (2013). Lymphoid malignancies: another face to the Janus kinases. Blood Rev, 27, 63-70.   DOI
39 Saeed HM, Alanazi MS, Parine NR, et al (2013). Matrix metalloproteinase-2 (-1306 c>t) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev, 14, 6025-30.   DOI   ScienceOn
40 Sanii S, Saffar H, Tabriz HM, et al (2012). Expression of matrix metalloproteinase-2, but not caspase-3, facilitates distinction between benign and malignant thyroid follicular neoplasms. Asian Pac J Cancer Prev, 13, 2175-8.   DOI
41 Sfar S, Saad H, Mosbah F, Gabbouj S, Chouchane L (2007). TSP1 and MMP9 genetic variants in sporadic prostate cancer. Cancer Genet Cytogenet, 172, 38-44.   DOI
42 Srivastava P, Kapoor R, Mittal RD (2013). Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India. Urol Oncol, 31, 247-54.   DOI
43 Soriano G, Heaney M (2013). Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications. Curr Opin Hematol, 20, 169-75.   DOI
44 Sugimoto M, Yoshida S, Kennedy S, et al (2006). Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig, 13, 523-9.
45 Szczudlik P, Borratynska A (2010). Association between the-1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population. Neurol Neurochir Pol, 44, 350-7.
46 Tefferi A, Vainchenker W (2011). Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol, 29, 573-82.   DOI
47 Vasku A, Goldbergova M, Izakovicova Holla L, et al (2004). A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol, 22, 585-91.   DOI
48 Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE (1994). Tumor invasion, proteolysis and angiogenesis. J Neuro Oncol, 18, 89-103.   DOI
49 Travaglino E, Benatti C, Malcovati L, et al (2008). Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol, 80, 216-26.   DOI
50 Vairaktaris E, Vassiliou S, Nkenke E, et al (2008). A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol, 34, 450-5.   DOI
51 Wadleigh M, Tefferi A (2010). Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol, 91, 174-9.   DOI   ScienceOn
52 Wagenaar-Miller RA, Gorden L, Matrisian LM (2004). Matrix metalloproteinases in colorectal cancer: is it worth talking about?. Cancer Metastasis Rev, 23, 119-35.   DOI
53 Wang J, Warzecha D, Wilcken D, Wang XL (2001). Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin Sci (Lond), 101, 87-92.   DOI
54 Wang Y, Fang S, Wei L, et al (2005). No association between the C-1562T polymorphism in the promoter of matrix metalloproteinase-9 gene and non-small cell lung carcinoma. Lung Cancer, 49, 155-61.   DOI
55 Yang TF, Guo L, Wang Q (2014). Meta-analysis of associations between four polymorphisms in the matrix metalloproteinases gene and gastric cancer risk. Asian Pac J Cancer Prev, 15, 1263-7.   DOI   ScienceOn
56 Woo M, Park K, Nam J, Kim JC (2007). Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol, 22, 1064-70.   DOI
57 Wu CY, Wu MS, Chen YJ, et al (2007). Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer, 43, 799-808.   DOI   ScienceOn
58 Xiaoping M, YuAC (2003). Functional polymorphism in the matrix metalloproteinase-2 gene promoter (1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res, 63, 3987-90.
59 Yari K, Rahimi Z, Moradi MT, Rahimi Z (2014). The MMP-2-735 C allele is a risk factor for susceptibility to breast cancer. Asian Pac J Cancer Prev, 15, 6199-203.   DOI
60 Yu C, Zhou Y, Miao X, et al (2004). Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res, 64, 7622-8.   DOI
61 Yu XF, Han ZC (2006). Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies. Histol Histopathol, 21, 519-31.
62 Zhang B, Ye S, Herrmann SM, et al (1999). Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 99, 1788-94.   DOI
63 Zhang B, Henney A, Eriksson P, et al (1999). Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet, 105, 418-23.   DOI